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Sickle	  cell	  disease	  (SCD)	  is	  a	  genetic	  disorder	  of	  growing	  global	  public	  health	  importance.1	  More	  than	  
300,000	  homozygous	  neonates	  (HbSS)	  suffering	  from	  sickle	  cell	  anaemia	  (SCA)	  -­‐	  the	  most	  common	  
form	  of	  SCD	  globally1	  -­‐	  are	  born	  every	  year,	  three-­‐quarters	  being	  born	  in	  Sub-­‐Saharan	  Africa.2	  Recent	  
estimates	   based	   on	   demographic	   projections	   suggest	   that	   this	   number	   could	   rise	   to	   400,000	   by	  
2050.3	  Relatively	  little	  is	  known	  about	  the	  natural	  history	  of	  SCD,	  particularly	  in	  Africa,	  and	  about	  the	  
epidemiology	   of	   clinically	   relevant	   forms	   of	   SCD	   -­‐	   HbSC	   disease	   and	   HbS-­‐β-­‐thalassaemia	   in	  
particular.4	   Even	   in	   resource-­‐rich	   regions,	   it	   can	   be	   difficult	   to	   estimate	   the	   burden	   of	   SCD	  
accurately.5	  The	  difficulties	  are	  even	  greater	  in	  high-­‐burden	  resource-­‐poor	  countries	  where	  data	  on	  
mortality	  rates	  of	  SCD	  patients	  are	  very	  limited,6	  meaning	  that	  it	  is	  currently	  impossible	  to	  produce	  a	  
credible	  estimate	  of	  the	  total	  number	  of	  individuals	  currently	  affected	  by	  SCD	  globally.	  	  	  	  	  
	  
Positive	  advances	  have	  recently	  been	  made	  towards	   increasing	  awareness	  about	  SCD.	   In	  2006,	  the	  
World	  Health	  Organization	  recognised	  SCD	  as	  a	  global	  public	  health	  problem	  while	  a	  few	  years	  later,	  
the	  63rd	  World	  Health	  Assembly	  adopted	  a	  resolution	  on	  the	  prevention	  and	  management	  of	  birth	  
defects,	  including	  SCD.	  September	  has	  become	  “sickle	  cell	  awareness	  month”	  in	  the	  USA,	  while	  the	  
19th	  of	   June	  has	  been	  delegated	   “World	   Sickle	  Cell	  Day”	  by	   the	  United	  Nations.	   Finally,	   since	   the	  
2010	   edition	   of	   the	   Global	   Burden	   of	   Diseases,	   Injuries,	   and	   Risk	   Factors	   Study,	   SCD	   has	   been	  
included	   in	  this	  comprehensive	  and	  systematic	  evidence-­‐based	  assessment	  of	  the	  burden	  of	  major	  
diseases	  and	  injuries.	  However,	  the	  impact	  of	  these	  changes	  has	  been	  limited,	  particularly	  from	  the	  
perspective	  of	  patients	  living	  in	  resource-­‐poor	  regions.	  
	  
In	   recent	   decades,	   notable	   improvements	   have	   been	   achieved	   regarding	   the	   diagnosis	   and	  
treatment	   of	   SCD	   in	   high-­‐	   and	   middle-­‐income	   countries	   including	   the	   introduction	   of	   penicillin	  
prophylaxis	   in	   the	  under-­‐5s,	  primary	  stroke	  prevention	  using	   transcranial	  Doppler	  ultrasonography	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and	  regular	  transfusions,	  and	  the	  use	  of	  hydroxyurea	  to	  reduce	  the	  frequency	  of	  acute	  complications	  
in	   children	   and	   adults.	   Early	   diagnosis,	   particularly	   through	   national	   screening	   programmes	   in	  
countries	   such	   as	   the	   UK	   and	   USA,	   has	   facilitated	   the	   implementation	   of	   these	   interventions.	  
Together	  with	  advances	  in	  general	  medical	  care,	  this	  has	  led	  to	  almost	  universal	  survival	  beyond	  the	  
age	  of	  18	  in	  these	  countries,	  in	  contrast	  to	  almost	  certain	  death	  before	  the	  age	  of	  10	  in	  the	  1950s;	  
however,	  this	  encouraging	  picture	  needs	  to	  be	  balanced	  by	  i)	  the	  reality	  that,	  even	  with	  the	  best	  of	  
care,	   life	   expectancy	   is	   still	   reduced	   by	   20	   to	   30	   years;	   ii)	   the	   huge	   financial	   costs	   of	   routine	  
treatment	   and	   emergency	   care	   for	   patients	   with	   SCD;	   iii)	   a	   relatively	   poor	   quality	   of	   life	   during	  
adulthood;	   and	   iv)	   the	   fact	   that	   the	   huge	   social	   and	   psychological	   impact	   of	   SCD	   on	   patients	   and	  
their	   families	   remains	   under-­‐appreciated.	  Whereas,	   a	   large	   number	   of	   small-­‐molecule	   drugs	   have	  
been	   designed	   specifically	   for	   various	  malignant	   diseases,	   no	   new	  drugs	   have	   been	   designed	   that	  
specifically	  target	  the	  pathophysiology	  of	  SCD	  and	  there	  is	  therefore	  a	  pressing	  need	  to	  develop	  new	  
pharmaceutical	  agents	  based	  on	  advances	  in	  molecular	  technologies.	  
	  
The	  situation	  in	  Sub-­‐Saharan	  Africa	  is	  alarming.	  Across	  large	  parts	  of	  the	  region,	  the	  birth	  prevalence	  
of	   SCD	   exceeds	   1%,	   fertility	   rates	   remain	   high,	   health	   infrastructures	   are	   poorly	   developed,	   and	  
educational	  opportunities	  are	  limited,	  contributing	  to	  sustain	  inaccurate	  beliefs	  about	  the	  nature	  of	  
the	  disease	  and	   its	   inheritance.	   In	   line	  with	   the	  4th	  Millennium	  Development	  Goal,	  many	  countries	  
within	   the	   region	  have	   achieved	   substantial	   reductions	   in	   childhood	  mortality.	  While	   undoubtedly	  
positive,	   one	   direct	   consequence	   is	   that	   an	   increasing	   number	   of	   babies	   born	   with	   SCD	   in	   Sub-­‐
Saharan	  Africa	  are	  now	  surviving	  into	  later	  childhood,	  yet	  a	  lack	  of	  diagnostic	  and	  treatment	  facilities	  
means	   that	  many	  are	  not	   receiving	   the	  health	   care	   that	   they	   require	  and	  will	   suffer	  unnecessarily	  
from	   severe	   clinical	   complications,	   including	   recurrent	   pain,	   vasculopathy,	   heart	   disease,	   renal	  
complications,	  acute	  chest	  syndrome	  and	  priapism.	  In	  addition,	  the	  lack	  of	  detailed	  epidemiological	  
data,	   cost-­‐effectiveness	   studies,	   mortality	   and	   morbidity	   data	   means	   that	   the	   evidence-­‐base	   to	  
support	  financial	  and	  political	  engagement	  is	  weak.	  
	  
The	  research	  and	  clinical	  communities	  working	  on	  SCD	  face	  a	  difficult	  choice.	  One	  option,	  roughly	  in	  
line	  with	  current	  public	  health	  agendas	  but	  unacceptable	  in	  our	  view,	  would	  be	  to	  wait	  for	  a	  greater	  
evidence	   to	   be	   assembled	   before	   taking	   action.	   An	   improved	   cheap,	   reliable	   and	   rapid	   diagnostic	  
test	  for	  SCD	  would	  be	  a	  key	  development.	  Nevertheless,	  considering	  the	  numerous	  public	  health	  and	  
political	  challenges	  that	  African	  countries	  are	  currently	  facing	  (including	  the	  current	  Ebola	  outbreak	  
and	  polio	  eradication	  efforts)	  and	  the	  relative	  neglect	  from	  which	  SCD	  is	  still	  suffering,	  the	  prospects	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of	  significant	  short-­‐term	  improvements	  for	  patients	  suffering	  from	  SCD	  in	  Sub-­‐Saharan	  Africa	  seem	  
very	  limited.	  	  
	  
The	   alternative,	   which	   we	   favour,	   would	   be	   to	   establish	   an	   immediate	   concerted	   international	  
commitment	  from	  governments,	  funding	  agencies,	  pharmaceutical	  companies	  and	  the	  research	  and	  
medical	  communities	  to	  develop	  a	  specific	  public	  health	  agenda	  for	  Sub-­‐Saharan	  Africa	   in	  order	  to	  
scale	   up	   available	   interventions	   and	   reduce	   the	   health	   burden	   of	   SCD.7	   A	   good	   example	   of	   the	  
benefits	  of	  such	  a	  proactive	  approach	  is	  provided	  by	  Graham	  Serjeant’s	  Jamaican	  cohort	  of	  100,000	  
neonates	  followed	  since	  the	  early	  1970s.8	  Alongside	  major	  improvements	  in	  the	  life-­‐expectancy	  and	  
quality	   of	   life	   of	   patients	   born	   with	   SCD,	   this	   study	   -­‐	   initiated	   with	   financial	   support	   from	   UK	  
institutions	   -­‐	   allowed	   (and	   still	   does	   allow)	   the	   gathering	   of	   valuable	   data	   on	   the	   epidemiology,	  
clinical	   course	   and	   phenotypic	   diversity	   of	   the	   disease.4	   There	   is	   growing	   evidence	   that	   the	  
introduction	  of	  newborn	   screening	   in	  high-­‐risk	  populations	  and	   the	   implementation	  of	   simple	  and	  
affordable	   interventions	  similar	   to	  those	  successfully	  used	   in	  high-­‐income	  countries	  could	  save	  the	  
lives	   of	  many	   thousands	  of	   children	   in	  African	   countries	   and	   result	   in	   significant	   improvements	   in	  
their	   quality	   of	   life	   throughout	   childhood	   and	   adulthood.9,10	   To	   date,	   no	   African	   country	   has	  
implemented	   a	   nationwide	   newborn	   screening	   programme	   nor	   introduced	   the	   systematic	   use	   of	  
penicillin	   prophylaxis	   and	   vaccination	   against	   Streptococcus	   pneumoniae	   and	   Haemophilus	  
influenzae	   type	   b	   for	   all	   children	   with	   SCD.	   This	   would	   be	   particularly	   useful	   in	   Nigeria	   and	   the	  
Democratic	  Republic	  of	  the	  Congo,	  where	  45%	  of	  all	  affected	  births	  currently	  occur.3	  Several	  global	  
and	   regional	   networks	   bringing	   together	   clinicians,	   researchers	   and	   patients,	   including	   the	   Global	  
Sickle	  Cell	  Disease	  Network	  (GSCDN)	  and	  the	  Sickle	  Cell	  Disease	  Research	  Network	  of	  Central	  Africa	  
(REDAC),	  have	  already	  been	  set	  up	  but	  their	  impact	  will	  remain	  limited	  without	  further	  financial	  and	  
political	  support.	  
	  
The	   benefits	   of	   better	   prevention	   and	   management	   of	   SCD	   in	   Africa	   would	   inevitably	   have	   a	  
substantial	  public	  health	  impact	  globally.	  We	  therefore	  advocate	  for	  the	  development	  of	  a	  proactive	  
public	  health	  agenda	  to	  reduce	  the	  long-­‐term	  burden	  of	  SCD	  in	  Africa.	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